Loading
Cardiac Tumors and Thrombi · Journal article
Stroke · July 2, 2026
A consensus or society position rather than new primary data.
This scientific statement synthesizes evidence from secondary analyses of randomized trials on anticoagulation versus non-anticoagulation strategies in patients with LV systolic dysfunction and ischemic stroke without detected intracardiac thrombus. Anticoagulation is associated with lower incident stroke risk but offers no net benefit for primary prevention; for secondary prevention post-stroke, anticoagulation may offer net benefit over antiplatelet therapy, though individualized, shared decision-making is recommended.
Scientific statement with narrative summary and meta-analysis of secondary analyses of randomized clinical trials. Patients with LV systolic dysfunction (LVEF ≤40% or wall motion abnormality) and ischemic stroke without intracardiac thrombus, derived from secondary analyses of randomized clinical trials.. Intervention: Anticoagulation strategies. Compared with: Non-anticoagulation strategies and antiplatelet therapy.
Anticoagulation associated with lower risk of incident stroke in LV dysfunction without thrombus No net benefit of anticoagulation over non-anticoagulation for primary stroke prevention in this population Anticoagulation may be associated with lower recurrent stroke risk compared with antiplatelet therapy post-stroke
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
A scientific statement synthesizing evidence on anticoagulation management in LV dysfunction without intracardiac thrombus, providing best practice recommendations rather than presenting new primary data.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Left ventricular (LV) systolic dysfunction, defined here as reduced LV ejection fraction ≤40% or left wall motion abnormality, is commonly found in patients with ischemic stroke. Although there is an increased risk of incident and recurrent embolic stroke among patients with LV dysfunction without thrombus detected, the data supporting anticoagulation in these patients are limited. In this scientific statement, we summarize the latest evidence regarding the risk of incident and recurrent stroke in patients with LV dysfunction as well as best practice recommendations regarding the management of this population after stroke. We provide a narrative summary and meta-analysis of secondary analyses of randomized clinical trials that evaluated outcomes following anticoagulation versus nonanticoagulation strategies. Whereas anticoagulation is associated with a lower risk of incident stroke in patients with LV dysfunction without thrombus, there remains no net benefit of this strategy over a nonanticoagulant strategy for primary stroke prevention. For patients with stroke and LV dysfunction, anticoagulation may be associated with a lower risk of recurrent stroke and a net benefit when compared with antiplatelet therapy. Anticoagulation treatment decisions in these patients may involve individualized consideration, shared decision-making between patients and healthcare professionals upon discussing risks and benefits, and multidisciplinary collaboration between cardiology and neurology clinicians to optimize cardiac and brain health. As a key modifiable stroke risk factor and therapeutic target, LV dysfunction represents a target for future research.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.